CClinicalTrials.gg
CompletedNCT02806492Updated Jun 8, 2017

Parameters of Cerebral Perfusion

An interventional study of 50-100ug phenylephrine before CPB and 50-100ug phenylephrine during CPB in Cerebral Perfusion, Cerebral Oxygenation and Cardiopulmonary Bypass, sponsored by UMC Utrecht. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by UMC Utrecht · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2016, registered Jun 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether cerebral blood flow and cerebral tissue oxygenation is most dependent on cardiac output or on mean arterial pressure in patients undergoing cardiac surgery with the use of cardiopulmonary bypass.

02

Conditions studied

  • Cerebral Perfusion
  • Cerebral Oxygenation
  • Cardiopulmonary Bypass
03

In context

Lead sponsor

UMC Utrecht is the lead sponsor of 350 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Undergoing cardiopulmonary bypass for CABG a
  • having an appropriate temporal bone window for reliable TCD monitoring
  • needing pharmacological intervention because of hypotension before going on CPB.

Exclusion criteria

Exclusion Criteria:

  • requiring hypothermia during surgery
  • requiring emergency surgery
  • contraindication for phenylephrine,
  • having known brain pathology (e.g. Cerebral Vascular Accident (CVA) or increased intracranial pressure
  • having a history of severe carotid artery stenosis.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Patient for cardiac surgery

    All patient undergo the 5 different intervention in a randomised matter.

    Other: 50-100ug phenylephrine before CPB · Other: 50-100ug phenylephrine during CPB · Other: decreasing CPB flow · Other: Decreasing CPB flow AND 50-100ug phenylephrine · Other: Increasing CPB flow

Interventions

  • Other50-100ug phenylephrine before CPB

    In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP \<60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.

  • Other50-100ug phenylephrine during CPB

    In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.

  • Otherdecreasing CPB flow

    With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.

  • OtherDecreasing CPB flow AND 50-100ug phenylephrine

    In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.

  • OtherIncreasing CPB flow

    In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.

06

What researchers measure

Primary outcomes

  1. regional cerebral oxygen saturation

    Time frame: During surgery

  2. mean velocity of blood flow of the middle cerebral artery

    Time frame: During surgery

07

Study locations

1 site
  • UMC Utrecht
    Utrecht, 3584CX, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02806492
Lead sponsor
UMC Utrecht
Responsible party
Dr. B. van Zaane (MD PhD, UMC Utrecht) — Principal investigator
First posted
Jun 20, 2016
Start date
Jan 2016
Primary completion
Mar 17, 2017
Completion
Mar 17, 2017
Last update
Jun 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion